Talditercept alfa

DB16337InvestigationalProtein Based Therapies

Talditercept alfa is under investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy).

Mechanism: Pharmacologically active on Growth/differentiation factor 8
Curator reviewed
Also known as: Adnectin, anti-(human growth differentiation factor 8) (synthetic clone prd-1474 fibronectin type iii tenth domain (10fn3)-based isoform · Bivalent Anti-Human Myostatin Adnectin-Igg1 · Bms-986089 (fully human anti-myostatin adnectin) · Immunoglobulin g1 (human fc fragment) fusion protein with peptide (synthetic 17-amino acid linker) fusion protein with adnectin, anti-(human growth differentiation factor 8) (human clone bms-986089 fibronectin tenth type iii domain-derived), dimer · Taldefgrobep alfa
Code names: BHV-2000 · BMS-986089 · RO-7239361

Resolves to

Compound

UNII766C38JSARCAS1580555-26-5

Targets

O14793MSTN

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Talditercept alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account